Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 48 entries
View as:

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Phase: N/A Priority: Normal
NCT ID: NCT03103919 Org: User:
Start: 03/16/17 End: 01/02/18 Due: 01/02/19

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT03559673 Org: User:
Start: - End: - Due: -

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02227355 Org: User:
Start: 09/30/14 End: 06/30/16 Due: 06/30/17

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

Phase: N/A Priority: Normal
NCT ID: NCT01390220 Org: User:
Start: 06/30/11 End: 03/31/17 Due: 03/31/18

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT04075409 Org: User:
Start: 09/30/19 End: 12/27/19 Due: 12/27/20

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Phase: N/A Priority: Normal
NCT ID: NCT02161185 Org: User:
Start: 05/31/14 End: 05/31/15 Due: 05/31/16

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03605082 Org: User:
Start: 07/25/18 End: 03/11/19 Due: 03/11/20

Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood

Phase: N/A Priority: Normal
NCT ID: NCT02306629 Org: User:
Start: 11/30/14 End: 04/30/15 Due: 04/30/16

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03373383 Org: User:
Start: 02/12/18 End: 01/30/20 Due: 01/30/21

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02905006 Org: User:
Start: 08/31/16 End: 07/31/17 Due: 07/31/18

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT04013191 Org: User:
Start: 07/09/19 End: 10/03/19 Due: 10/03/20

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03357471 Org: User:
Start: 11/03/17 End: 07/02/18 Due: 07/02/19

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03895385 Org: User:
Start: 04/02/19 End: 10/04/19 Due: 10/04/20

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02804763 Org: User:
Start: 06/02/16 End: 11/19/18 Due: 11/19/19

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Phase: N/A Priority: Normal
NCT ID: NCT01529034 Org: User:
Start: 07/31/12 End: - Due: -

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Phase: N/A Priority: Normal
NCT ID: NCT02346240 Org: User:
Start: 02/11/15 End: 12/17/18 Due: 12/17/19

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03168984 Org: User:
Start: 05/05/17 End: 08/14/17 Due: 08/14/18

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT02687711 Org: User:
Start: 02/01/16 End: 07/15/20 Due: 07/15/21

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03051217 Org: User:
Start: 02/21/17 End: 01/16/19 Due: 01/16/20

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02969525 Org: User:
Start: 10/31/16 End: 07/31/18 Due: 07/31/19

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT02495844 Org: User:
Start: 07/31/15 End: 07/31/17 Due: 07/31/18

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

Phase: N/A Priority: Normal
NCT ID: NCT01999777 Org: User:
Start: 11/30/13 End: 08/31/15 Due: 08/31/16

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03464227 Org: User:
Start: 02/16/18 End: 12/01/18 Due: 12/01/19

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

Phase: N/A Priority: Normal
NCT ID: NCT03707717 Org: User:
Start: 10/15/18 End: 06/05/19 Due: 06/05/20

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT04126343 Org: User:
Start: 10/23/19 End: 05/22/20 Due: 05/22/21